Skip to main content

06-06-2020 | EULAR 2020 | Conference coverage | Video

Researcher comment: SELECT-PsA-2

share
SHARE

Philip Mease describes the findings from the SELECT-PsA-2 trial of upadacitinib in patients with psoriatic arthritis and an inadequate response to biologic DMARDs (6.18).

Read the transcript

Related content

05-06-2020 | EULAR 2020 | Conference coverage | News

Upadacitinib shows promise for PsA

05-06-2020 | EULAR 2020 | Conference coverage | Video

Researcher comment: SELECT-PsA-1